← Leaderboards
Stevan Pecic
California State University Fullerton
$932,369
Attributed
$932,369
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $207.7K · FY2020–25$250K$187.5K$125K$62.5K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$932,369 · 2
By mechanism
R16$506,369 · 1
SC2$426,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “In Vitro”
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Leonard Freedmand · Leidos Biomedical Research, Inc.$68,796,314
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$41,541,738
- John Damon Chodera · Sloan-Kettering Inst Can Research$34,949,884
- Tony Moody · Duke University$34,777,314
Research focus
In VitroLibrariesFutureInvestigationIn VivoLeadDesignEpoxide HydrolaseInflammationIn SilicoFaah InhibitorAnalogFoundationsFatty Acid Amide HydrolaseAnti-Inflammatory AgentsAbsence Of Pain SensationChronic PainBenzothiazoleEnzymesBiologicalCaliforniaDrug KineticsAnalgesicsLigands
Grant awards (7)
Designed Multiple Ligands as Non-opioid Analgesics for Treating Chronic Pain$144,059
R16 · FY2025 · GM · contact PI
Designed Multiple Ligands as Non-opioid Analgesics for Treating Chronic Pain$144,111
R16 · FY2024 · GM · contact PI
Designed Multiple Ligands as Non-opioid Analgesics for Treating Chronic Pain$63,572
R16 · FY2024 · GM · contact PI
Designed Multiple Ligands as Non-opioid Analgesics for Treating Chronic Pain$154,627
R16 · FY2023 · GM · contact PI
Development of dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors as a Promising Therapeutic Strategy for the Treatment of Acute and Chronic Pain$142,000
SC2 · FY2022 · GM · contact PI
Development of dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors as a Promising Therapeutic Strategy for the Treatment of Acute and Chronic Pain$142,000
SC2 · FY2021 · GM · contact PI
Development of dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors as a Promising Therapeutic Strategy for the Treatment of Acute and Chronic Pain$142,000
SC2 · FY2020 · GM · contact PI